1. Home
  2. CYRX vs ENTA Comparison

CYRX vs ENTA Comparison

Compare CYRX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CYRX

CryoPort Inc.

HOLD

Current Price

$10.55

Market Cap

419.3M

Sector

Health Care

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$13.29

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYRX
ENTA
Founded
1999
1995
Country
United States
United States
Employees
1100
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
419.3M
374.6M
IPO Year
2008
2012

Fundamental Metrics

Financial Performance
Metric
CYRX
ENTA
Price
$10.55
$13.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$13.31
$20.40
AVG Volume (30 Days)
409.4K
106.1K
Earning Date
05-04-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
156.22
29.93
EPS
1.40
N/A
Revenue
$176,177,000.00
$102,814,000.00
Revenue This Year
$11.06
$7.76
Revenue Next Year
$8.45
N/A
P/E Ratio
$7.28
N/A
Revenue Growth
N/A
16.48
52 Week Low
$5.31
$4.96
52 Week High
$11.45
$17.15

Technical Indicators

Market Signals
Indicator
CYRX
ENTA
Relative Strength Index (RSI) 68.70 46.53
Support Level $9.18 $13.02
Resistance Level $11.33 $13.76
Average True Range (ATR) 0.41 0.67
MACD 0.08 -0.05
Stochastic Oscillator 82.83 22.97

Price Performance

Historical Comparison
CYRX
ENTA

About CYRX CryoPort Inc.

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: